MedPath

Phase II clinical trial to Assess the Safety and Efficacy of YHD1023 in Patients with Erectile Dysfunctio

Not Applicable
Completed
Conditions
Diseases of The genitoruinary system
Registration Number
KCT0001049
Lead Sponsor
Yuhan
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Male
Target Recruitment
112
Inclusion Criteria

Male volunteers of aged 20 years and older with history of organic erectile dysfunction of at least 6 months duration

- Anticipate having the same adult female sexual partner, who have no possibility of being pregnant or breast-feeding and take steps to prevent conception during the study

- The patient or legally authorized representative must sign a written informed consent, prior to the any procedure, using a form that is approved by the local Institutional Review Board after detail explanation of the purpose, contents, and characteristic of the drug

Exclusion Criteria

- Have history of stroke, myocardial infarction, or Coronary Artery Bypass Graft surgery within the last 6 months

- Have history of cardiac failure, unstable angina, or life-threatening arrhythmia within the last 6 months

- Shown tachyarrhythmia, heart rate over 100 times/min(e.g. arterial fibrillation, flutter)

- Presence of hypotension as evidenced by SBP/DBP < 90/50mmHg or uncontrollable hypertension as evidenced by SBP/DBP > 170/100mmHg

- Have history of symptomatic postural hypotension within the last 6 months

- Have history of spinal cord injury, radical prostatectomy, or pelvic surgery

- Subject who is judged to be ineligible according to their physical checkup(medical history, physical examination, ECG, laboratory values and etc.) within 56 days prior to the first administration

- Participated in any other clinical trials within 30 days prior to the first administration

- Subject who is judged to be ineligible by principal investigator or sub-investigator due to mental disorder or continuous drug abuse

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change from baseline in the International Index of Erectile Function(IIEF) - Erectile Function(EF) domain score at week 8
Secondary Outcome Measures
NameTimeMethod
Mean change from baseline in other Question of International Index of Erectile Function(IIEF) domain at week 8 ;Percentage of Improved patients from baseline in Question 2 & Question 3 of Sexual Encounter Profile(SEP) at week 8
© Copyright 2025. All Rights Reserved by MedPath